Clinical Trial Update: Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of booster doses for new formulations of GSK's DTPa-HBV-IPV/Hib vaccine (GSK217744) in children receiving acel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type
• Hepatitis B
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-HBV-IPV/Hib vaccine (GSK217744)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2014-07-28